HC Wainwright Has Bullish Forecast for SGMT FY2026 Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT) – Stock analysts at HC Wainwright upped their FY2026 EPS estimates for shares of Sagimet Biosciences in a report issued on Monday, October 5th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($1.31) for the year, up from their prior estimate of ($1.48). HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ Q4 2026 earnings at ($0.27) EPS, FY2027 earnings at ($1.03) EPS and FY2028 earnings at ($0.64) EPS.

Sagimet Biosciences (NASDAQ:SGMT) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01).

Several other equities analysts also recently commented on the company. Wall Street Zen downgraded Sagimet Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Citigroup restated a “market outperform” rating on shares of Sagimet Biosciences in a research note on Thursday, October 1st. Barclays raised Sagimet Biosciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $8.00 to $18.00 in a report on Wednesday, September 9th. Guggenheim increased their price objective on Sagimet Biosciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Sagimet Biosciences in a report on Thursday, October 1st. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Sagimet Biosciences has an average rating of “Moderate Buy” and a consensus target price of $26.63.

Sagimet Biosciences Stock Up 1.4%

Shares of SGMT stock opened at $8.88 on Wednesday. The firm has a 50 day moving average price of $9.92 and a two-hundred day moving average price of $7.86. The company has a market capitalization of $551.98 million, a PE ratio of -6.94 and a beta of 3.46. Sagimet Biosciences has a 12-month low of $4.50 and a 12-month high of $11.45.

Insider Transactions at Sagimet Biosciences

In related news, insider Elizabeth Rozek sold 10,545 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $7.76, for a total value of $81,829.20. Following the completion of the sale, the insider directly owned 224,414 shares in the company, valued at approximately $1,741,452.64. The trade was a 4.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David Happel sold 64,051 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $7.76, for a total value of $497,035.76. Following the sale, the chief executive officer directly owned 741,570 shares in the company, valued at $5,754,583.20. This represents a 7.95% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 113,646 shares of company stock valued at $920,491. 11.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sagimet Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Baird Financial Group Inc. lifted its holdings in shares of Sagimet Biosciences by 19.8% in the second quarter. Baird Financial Group Inc. now owns 15,677 shares of the company’s stock worth $121,000 after acquiring an additional 2,591 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Sagimet Biosciences by 344.1% during the 1st quarter. Bank of America Corp DE now owns 43,858 shares of the company’s stock valued at $229,000 after purchasing an additional 33,982 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Sagimet Biosciences during the 2nd quarter valued at approximately $315,000. AWM Investment Company Inc. acquired a new position in Sagimet Biosciences during the 2nd quarter worth approximately $618,000. Finally, Dimensional Fund Advisors LP increased its position in Sagimet Biosciences by 99.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company’s stock worth $1,415,000 after purchasing an additional 135,178 shares in the last quarter. Institutional investors own 87.86% of the company’s stock.

Key Headlines Impacting Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to a loss of $0.27 from a loss of $0.32, suggesting a better-than-previously-expected near-term earnings outlook. HC Wainwright Has Optimistic Opinion of SGMT FY2026 Earnings
• Positive Sentiment: The analyst also improved its loss estimates for FY2026, FY2027 and FY2028 to $1.31, $1.03 and $0.64 per share, respectively, from prior estimates of $1.48, $1.22 and $0.85. Smaller projected losses indicate improving profitability expectations. HC Wainwright Has Optimistic Opinion of SGMT FY2026 Earnings
• Positive Sentiment: HC Wainwright continues to forecast a transition to profitability, projecting positive EPS of $0.89 in FY2029, up from $0.81 previously. HC Wainwright Has Strong Forecast for SGMT FY2029 Earnings
• Neutral Sentiment: The analyst estimates Sagimet will remain unprofitable through FY2028, while the company’s current-year consensus loss is $1.17 per share. This highlights that the investment case still depends on successful future execution and commercialization.
• Negative Sentiment: HC Wainwright slightly reduced its FY2030 EPS forecast to $2.28 from $2.34. However, the estimate remains profitable and follows its increased FY2029 forecast, limiting the negative significance. HC Wainwright Has Strong Forecast for SGMT FY2029 Earnings

About Sagimet Biosciences

Sagimet Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target fatty acid synthase (FASN), an enzyme involved in the production of fatty acids. The company’s research is aimed at treating diseases associated with abnormal lipid metabolism and excess fat production.

Sagimet’s lead investigational product is denifanstat, an oral, selective FASN inhibitor formerly known as TVB-2640. The company is evaluating denifanstat primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can involve inflammation, fat accumulation and fibrosis.